PDCD1 and neoplasm: In immunotherapy, the expression levels of PD-1 and its ligand PD-L1 serve as critical indicators for evaluating tumor immunosuppression and predicting the efficacy of ICIs.PD-1 is primarily expressed on the surface of activated T cells, B cells, and NK cells.